000288780 001__ 288780
000288780 005__ 20250318095603.0
000288780 0247_ $$2doi$$a10.1093/mutage/geae006
000288780 0247_ $$2pmid$$apmid:38422374
000288780 0247_ $$2ISSN$$a0267-8357
000288780 0247_ $$2ISSN$$a1464-3804
000288780 037__ $$aDKFZ-2024-00463
000288780 041__ $$aEnglish
000288780 082__ $$a610
000288780 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000288780 245__ $$aGenetic And Environmental Associations Of Nonspecific Chromosomal Aberrations.
000288780 260__ $$aOxford$$bOxford Univ. Press$$c2025
000288780 3367_ $$2DRIVER$$aarticle
000288780 3367_ $$2DataCite$$aOutput Types/Journal article
000288780 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1742288123_8523$$xReview Article
000288780 3367_ $$2BibTeX$$aARTICLE
000288780 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000288780 3367_ $$00$$2EndNote$$aJournal Article
000288780 500__ $$a#EA:Z999#LA:B062# / 2025 Mar 15;40(1):30-38
000288780 520__ $$aNonspecific structural chromosomal aberrations (CAs) are found in around 1% of circulating lymphocytes from healthy individuals but the frequency may be higher after exposure to carcinogenic chemicals or radiation. CAs have been used in the monitoring of persons exposed to genotoxic agents and radiation. Previous studies on occupationally exposed individuals have shown associations between the frequency of CAs in peripheral blood lymphocytes and subsequent cancer risk. The cause for CA formation are believed to be unrepaired or insufficiently repaired DNA double-strand breaks or other DNA damage, and additionally telomere shortening. CAs include chromosome (CSAs) and chromatid type aberrations (CTAs). In the present review, we first describe the types of CAs, the conventional techniques used for their detection and some aspects of interpreting the results. We then focus on germline genetic variation in the frequency and type of CAs measured in a genome-wide association study (GWAS) in healthy individuals in relation to occupational and smoking-related exposure compared to non-exposed referents. The associations (at p<10-5) on 1473 healthy individuals were broadly classified in candidate genes from functional pathways related to DNA damage response/repair, including PSMA1, UBR5, RRM2B, PMS2P4, STAG3L4, BOD1, COPRS and FTO; another group included genes related to apoptosis, cell proliferation, angiogenesis and tumorigenesis, COPB1, NR2C1, COPRS, RHOT1, ITGB3, SYK, and SEMA6A; a third small group mapped to genes KLF7, SEMA5A and ITGB3 which were related to autistic traits, known to manifest frequent CAs. Dedicated studies on 153 DNA repair genes showed associations for some 30 genes, expression of which could be modified by the implicated variants. We finally point out that monitoring of CAs is so far the only method of assessing cancer risk in healthy human populations, and the use of the technology should be made more attractive by developing automated performance steps and incorporating artificial intelligence methods into the scoring.
000288780 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000288780 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000288780 650_7 $$2Other$$aChromosomal damage
000288780 650_7 $$2Other$$aDNA repair
000288780 650_7 $$2Other$$acancer
000288780 650_7 $$2Other$$adouble-strand break
000288780 650_7 $$2Other$$agenetics
000288780 7001_ $$0P:(DE-He78)0681b959321f574e7ad1869cc3011346$$aNiazi, Yasmeen$$b1
000288780 7001_ $$aVodickova, Ludmila$$b2
000288780 7001_ $$aVodicka, Pavel$$b3
000288780 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b4$$eLast author$$udkfz
000288780 773__ $$0PERI:(DE-600)1497468-X$$a10.1093/mutage/geae006$$gp. geae006$$n1$$p30-38$$tMutagenesis$$v40$$x0267-8357$$y2025
000288780 909CO $$ooai:inrepo02.dkfz.de:288780$$pVDB
000288780 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000288780 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0681b959321f574e7ad1869cc3011346$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000288780 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000288780 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000288780 9141_ $$y2024
000288780 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000288780 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMUTAGENESIS : 2022$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000288780 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000288780 9202_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000288780 9201_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000288780 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000288780 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000288780 9200_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000288780 980__ $$ajournal
000288780 980__ $$aVDB
000288780 980__ $$aI:(DE-He78)Z999-20160331
000288780 980__ $$aI:(DE-He78)B062-20160331
000288780 980__ $$aI:(DE-He78)HD01-20160331
000288780 980__ $$aUNRESTRICTED